These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23200793)

  • 21. Guidance for handling and use of nanomaterials at the workplace.
    Heinemann M; Schäfer HG
    Hum Exp Toxicol; 2009 Jun; 28(6-7):407-11. PubMed ID: 19755453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of information in nanomaterial safety data sheets and development of international standard for guidance on preparation of nanomaterial safety data sheets.
    Lee JH; Kuk WK; Kwon M; Lee JH; Lee KS; Yu IJ
    Nanotoxicology; 2013 May; 7(3):338-45. PubMed ID: 22263625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing the role of science in the decision-making of the European Union.
    Allio L; Ballantine B; Meads R
    Regul Toxicol Pharmacol; 2006 Feb; 44(1):4-13. PubMed ID: 16266777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanotherapeutics--product development along the "nanomaterial" discussion.
    Wacker MG
    J Pharm Sci; 2014 Mar; 103(3):777-84. PubMed ID: 24481705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk management of nanomaterials.
    Gwinn MR; Tran L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(2):130-7. PubMed ID: 20077523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PBT assessment using the revised annex XIII of REACH: a comparison with other regulatory frameworks.
    Moermond CT; Janssen MP; de Knecht JA; Montforts MH; Peijnenburg WJ; Zweers PG; Sijm DT
    Integr Environ Assess Manag; 2012 Apr; 8(2):359-71. PubMed ID: 22006646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An analysis of the proposed REACH regulation.
    Petry T; Knowles R; Meads R
    Regul Toxicol Pharmacol; 2006 Feb; 44(1):24-32. PubMed ID: 16249048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanotoxicology and nanomedicine: making hard decisions.
    Linkov I; Satterstrom FK; Corey LM
    Nanomedicine; 2008 Jun; 4(2):167-71. PubMed ID: 18329962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically modified animals from life-science, socio-economic and ethical perspectives: examining issues in an EU policy context.
    Frewer LJ; Kleter GA; Brennan M; Coles D; Fischer AR; Houdebine LM; Mora C; Millar K; Salter B
    N Biotechnol; 2013 Jun; 30(5):447-60. PubMed ID: 23567982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Greener nanoscience: a proactive approach to advancing applications and reducing implications of nanotechnology.
    Hutchison JE
    ACS Nano; 2008 Mar; 2(3):395-402. PubMed ID: 19206562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. National Survey of Workplaces Handling and Manufacturing Nanomaterials, Exposure to and Health Effects of Nanomaterials, and Evaluation of Nanomaterial Safety Data Sheets.
    Kim J; Yu IJ
    Biomed Res Int; 2016; 2016():8389129. PubMed ID: 27556041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From cradle-to-grave at the nanoscale: gaps in U.S. regulatory oversight along the nanomaterial life cycle.
    Beaudrie CE; Kandlikar M; Satterfield T
    Environ Sci Technol; 2013 Jun; 47(11):5524-34. PubMed ID: 23668487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are environmental regulations keeping up with innovation? A case study of the nanotechnology industry.
    Fairbrother A; Fairbrother JR
    Ecotoxicol Environ Saf; 2009 Jul; 72(5):1327-30. PubMed ID: 19423165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A European nano-registry as a reliable database for quantitative risk assessment of nanomaterials? A comparison of national approaches.
    Pavlicek A; Part F; Rose G; Praetorius A; Miernicki M; Gazsó A; Huber-Humer M
    NanoImpact; 2021 Jan; 21():100276. PubMed ID: 35559789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Nano materials need stricter EU regulation].
    Forsberg E
    Lakartidningen; 2017 Jul; 114():. PubMed ID: 28675415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the increasing policy use of Impact Assessment in Europe likely to undermine efforts to achieve healthy public policy?
    Smith KE; Fooks G; Collin J; Weishaar H; Gilmore AB
    J Epidemiol Community Health; 2010 Jun; 64(6):478-87. PubMed ID: 20466716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights into possibilities for grouping and read-across for nanomaterials in EU chemicals legislation.
    Mech A; Rasmussen K; Jantunen P; Aicher L; Alessandrelli M; Bernauer U; Bleeker EAJ; Bouillard J; Di Prospero Fanghella P; Draisci R; Dusinska M; Encheva G; Flament G; Haase A; Handzhiyski Y; Herzberg F; Huwyler J; Jacobsen NR; Jeliazkov V; Jeliazkova N; Nymark P; Grafström R; Oomen AG; Polci ML; Riebeling C; Sandström J; Shivachev B; Stateva S; Tanasescu S; Tsekovska R; Wallin H; Wilks MF; Zellmer S; Apostolova MD
    Nanotoxicology; 2019 Feb; 13(1):119-141. PubMed ID: 30182766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modern regulatory impact analysis: the experience of the European Union.
    Ballantine B; Devonald B
    Regul Toxicol Pharmacol; 2006 Feb; 44(1):57-68. PubMed ID: 16307835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanomaterials in the environment: from materials to high-throughput screening to organisms.
    Thomas CR; George S; Horst AM; Ji Z; Miller RJ; Peralta-Videa JR; Xia T; Pokhrel S; Mädler L; Gardea-Torresdey JL; Holden PA; Keller AA; Lenihan HS; Nel AE; Zink JI
    ACS Nano; 2011 Jan; 5(1):13-20. PubMed ID: 21261306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.